Replies to post #77065 on Biotech Values

[DewDiligence]

Re: Latisse and off-label Lumigan

I think the crime srsmgja is referring to is insurance fraud, though it is not completely clear to me where the fraud is since a prescription does not, I believe, have a diagnosis on it.

That’s not how I interpreted srsmgja’s post; moreover, I was assuming that the hypothetical patient looking for enhanced eyelashes was self-pay.

The litigation risk that I would be concerned about is malpractice. If a doc prescribed Lumigan for eyelashes and there were a serious adverse event, the patient could sue with a claim that it was negligent to prescribe an off-label product when an FDA-approved product was readily available and presumably less likely to cause the observed SAE.